Pfizer Announces Trial Conclusion and 4 Stocks Hitting 52-Week Highs

Overstock.Com (NASDAQ:OSTK): Men seem to be the drivers of online commerce, reports Bloomberg. Men often use websites like Bonobos and Thrillist, for the convenience and a fast shopping experience. They are also a growing part of the $41 billion fashion e-commerce market by providing unique services. The shares closed at $11.26, up $0.33 or 3.02% on the day. They have traded in a 52-week range of $4.97 to $11.00.

Pfizer (NYSE:PFE) has completed a double-blind, placebo-controlled, randomized clinical trial intended to examine how effective and safe CHANTIX/CHAMPIX 1 mg BID in versus a placebo to help patients with a past or present diagnosis of Major Depressive Disorder quit smoking. The study met its primary and secondary efficacy endpoints. Subjects in the varenicline group had a higher likelihood of quitting at week 12, which was the primary endpoint, and at week 52, the key secondary endpoint. Also, psychiatric scales included for safety assessments did not reveal any difference between varenicline and placebo. The shares closed at $25.80, up $0.23 or 0.9% on the day. They have traded in a 52-week range of $18.15 to $25.62.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Prudential Public (NYSE:PUK): The Prudential Regulatory Authority, which is to be a division of the Bank of England beneath a new regulatory system for England’s financial industry, will not “seek to operate a zero-failure regime” for U.K. insurers, reports The Telegraph. The shares closed at $28.06, up $0.68 or 2.48% on the day. They have traded in a 52-week range of $17.11 to $27.81.

Sanofi-Aventis Sa (NYSE:SNY): In briefing documents scheduled before an advisory committee meeting on October 17, an FDA panel said, “Because of the potential risk of hepatotoxicity, mipomersen could not be approved without the necessary safeguards to restrict prescribing to certified prescribers who understand that mipomersen must be used only for treating patients in whom the benefit is thought to exceed this risk.” The documents outline a proposed Risk Evaluation and Mitigation Strategy, or REMS, for the drug that would restrict prescribing to only certified prescribers and dispensing of mipomersen to only certified pharmacies. The panel stated, “The REMS proposed above would support appropriate use of mipomersen, allowing it to be approved for use in the targeted patient population, a patient population with life threatening illness and limited therapeutic options, while protecting the larger hypercholesterolemic patient population.” The drug is in the process of being developed by Genzyme, which is a unit of Sanofi, together with Isis Pharmaceuticals (NASDAQ:ISIS). The shares closed at $45.19, up $1.55 or 3.55% on the day. They have traded in a 52-week range of $31.61 to $44.97.

Stewart Information (NYSE:STC): TELUS Financial Solutions has entered into a strategic alliance with Stewart Title Guaranty Co., which is a leader in the Canadian Title insurance industry. Stewart Title agreed to act as TELUS’ exclusive representative regarding advertisement, marketing, and promotion of Assyst Real Estate, which is TELUS’ proprietary web-based mortgage processing application for legal professionals. Beneath the arrangement, Stewart Title is to be the exclusive sales channel for Assyst Real Estate to the legal community, overseeing all sales and marketing efforts spanning Canada (excluding Quebec). TELUS plans to maintain the technology that supports Assyst Real Estate. The shares closed at $21.70, up $0.47 or 2.21% on the day. They have traded in a 52-week range of $8.98 to $21.66.

Don’t Miss: Are P&G Shares a Buy Today?